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1. INTRODUCTION 
 
 Efforts to innovate existing medication include the development of medicines with 
higher selectivity of action, less toxicity and side-effects, higher stability, a more favourable 
pharmacokinetic profile and improved patient compliance. Modern pharmaceutical 
technology is concentrated on new drug forms which are targeted to the exact site at the 
appropiate time, with maximum efficiency and with reduced side-effects. 
 The solubility properties of drugs and the dissolution of the active substance from 
dosage forms have a basic impact on the bioavailability of the product. Generally, only the 
dissolved pharmacon is able to absorb and the dissolution rate greatly affects the rate of 
transport processes if the dissolution is the slowest step in the LADMER system. 
Enhancement of the solubility of poorly-soluble drug substances is one of the most important 
tasks in pharmaceutical technology. With new material drug carriers and new technological 
processes, it is possible to achieve this. 
 Complexation is one of several ways to favourably enhance the physicochemical 
properties of pharmaceutical compounds. It may loosely be defined as the reversible 
association of substrate and ligand to form a new species. Cyclodextrins (CDs) are classical 
examples of compounds that form inclusion complexes. These complexes are formed when a 
”guest„ molecule is partially or fully incorporated into the cavity of a ”host„ molecule. When 
inclusion complexes are formed, the physicochemical parameters of the guest molecule are 
disguised or altered, and improvements in the solubility, stability, taste, safety and 
bioavailability of the molecule are commonly seen. 
 Pharmaceutical solid dispersion technology is generally accepted as a technique with 
which to enhance the dissolution characteristics of drugs with poor water solubility. For this 
purpose, the drug substance is dispersed in a water-soluble inert polymer matrix; at the higher 
surface area due to the presence of the polymer, sometimes the drug solubility and dissolution 
rate may increase. 
 This thesis is based on investigations of an anti-inflammatory drug nifluminic acid 
(NIF), with poor water solubility, to apply these technological procedures so as to increase its 
solubility and dissolution rate. Iervolino and co-workers applied CDs in 1:1 ratio, using three 
methods to reduce the gastric toxicity of NIF and could improve its safety profile. This thesis 
focused on the other possibilities of formulation of the drug. 
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2. EXPERIMENTAL AIMS 
 
The aims of the present work were as follows. 
In view of the poor water-solubility of a pharmaceutical ingredient, NIF, my aim was to 
increase its solubility and dissolution rate by applying different formulation methods. 
The first aim of the study was to prepare binary and ternary CD complexes at several mole 
and mass ratios and via three complexation methods. 
The second aim was to examine solid dispersion systems with solvent evaporation 
processes, such as vacuum- and spray-drying technologies. 
The third aim was to investigate the characteristic physicochemical properties, 
biopharmaceutical behaviour for solubility, dissolution rate and structural characteristics of 
the samples on the basis of the following: 
1. Preformulation studies on the products 
a. Recording the contact angles to establish their wettability 
b. Determination of the n-octanol/water partition coefficient to predict their 
permeability features 
c. Investigation of the saturation concentration in water to determine their 
solubility 
d. Analysis of the particle size  
2. In vitro investigations 
a. Determination of the solubility and the rate of dissolution of the drug in 
simulated media 
b. Determination of the membrane diffusion 
3. Structural evaluations 
a. Study of the Fourier transform-IR spectra, XRPD and thermal analysis 
(DSC and hot-stage microscopy (HSM)) 
 
3. MATERIALS 
3.1. Active substance: Nifluminic acid (NIF) 
 
NIF: 2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 
(G. Richter Ltd., Hungary) 
Chemical structure (see Fig. 1) 
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Fig. 1. Chemical structure of NIF 
 
Molecular formula:  C13H9F3N2O2 
Mw:    282.23 
Melting point:   205 ºC 
Original name:  Donalgin® 
Description:   a yellow, fine powder  
NIF, an anthranilic acid derivative, is a frequently used anti-inflammatory drug, which also 
has a weak analgetic effect. It is primarily used to treat different forms of rheumatism, e.g. 
rheumatoid arthritis and arthrosis, and to decrease other inflammatory phenomena. The usual 
single dose is 250 mg of NIF for adults, generally in capsules (e.g. Donalgin® capsule, G. 
Richter Ltd., Budapest, Hungary). It has some side-effects, such as nausea or vomiting. In 
cases of stomach ulcer, it may only be used under medical control. Three h after a 250 mg 
dose administered to 6 male volunteers as the first dose on day 10 of a 14-day 250 mg, 4 
times daily dosage regimen, the mean peak plasma concentration of radiolabelled NIF was 
123 µg/ml. According to the BCS, NIF can be considered a class II compound, i.e. a water-
insoluble, lipophilic and highly permeable compound. Since NIF is also widely prescribed for 
mild illnesses, the safety aspect becomes central and efforts should be made to optimize the 
overall drug pharmacological profile. 
 
3.2. Auxiliary materials 
 
 α-CD, β-CD, γ-CD, hydroxybutenyl-β-CD (HBU-β-CD), 2-hydroxypropyl-β-CD (HP-
β-CD), heptakis-2,6-di-O-methyl-β-CD (DIMEB) and randomly methylated-β-CD 
(RAMEB) (Cyclolab R&D Laboratory Ltd., Hungary); Captisol® (Cydex, Inc., USA). 
 polyvinylpyrrolidone (PVP): K-90, Mw: 1 300 000 (Pharmacopoeia Hungarica 7th 
Edition); C-30 (Mw ~ 58 000), K-25 (Mw ~ 34 000), C-15 (Mw ~ 8 000) (C/o ISP 
Customer Service GmbH, Germany) 
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 other chemicals, like acetone, ethanol, methanol are analitical purity (Spektrum 3D 
Ltd., Debrecen, Hungary). 
 
4. METHODS 
 
4.1. Preparation of the samples 
 
4.1.1. Cyclodextrin binary complexes 
 
The products were prepared in four different mole ratios (NIF:CD mole ratio = 2:1, 1:1, 
1:2 and 1:3). Physical mixtures (PMs): The plain drug and CD were mixed in a mortar and 
sieved through a 100 µm sieve. Two types of solvent method were applied (kneading and 
ultrasonication). Kneaded products (KPs): PMs of the drug and HP-β-CD were mixed with 
the same quantity of a solvent mixture of ethanol + water (1:1). They were kneaded until the 
bulk of the solvent mixture had evaporated. The ultrasonicated systems (USs): the PMs were 
dissolved in 50 % ethanol, placed in the Grant ultrasonic bath XB2 (England) for 1 h, dried 
and pulverized. After this, they were dried at room temperature and then at 105 oC, and were 
pulverized and sieved through a 100 µm sieve. 
 
4.1.2. Cyclodextrin ternary systems 
 
The three-component products were prepared in four different mole ratios (NIF:HP-β-CD 
mole ratio = 2:1, 1:1, 1:2 and 1:3), in all cases containing 15% (w/w) PVP K-90. Ternary 
physical mixtures (PMs+PVP): NIF, HP-β-CD and PVP were mixed in a mortar and sieved 
through a 100 µm sieve. Ternary kneaded products (KPs+PVP): PMs+PVP were mixed with 
the same quantity of a solvent mixture of ethanol + water (1:1), and were kneaded until the 
bulk of the solvent mixture had evaporated. After this, they were dried at room temperature 
and then at 105 oC, pulverized and sieved through a 100 µm sieve. 
 
4.1.3. PVP solid dispersions 
 
The two-component products were prepared in four different mass ratios (NIF:PVP mass 
ratio = 1:1, 1:2, 1:4 and 1:6). The PMs C-15, C-30 and K-25 were mixed, pulverized in a 
mortar and sieved through a 100 µm sieve. 
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Solid dispersions were prepared by using a vacuum dryer and spray dryer for solvent 
evaporation. The solvented products were prepared with drug:PVP K-25 mass ratios of 1:1, 
1:2, 1:4 and 1:6 (SP K-25). To a solution of NIF (1 g) in 30 ml of acetone, the appropriate 
amount of PVP K-25 was added. The minimum amount of methanol was added to solubilize 
the polymer. The solvents were removed under reduced pressure at 30 oC and the residue was 
dried under vacuum at room temperature for 3 h. The samples were pulverized and sieved 
through a 100 µm sieve. 
The spray-dried samples (SPDs) were prepared by using a Büchi Mini Dryer B-191 
(Switzerland), at 165 oC inlet and 86 oC outlet temperature with a compressed air flow of 600 
l/min and a nozzle diameter of 0.5 mm as solvent evaporator. The aspirator rate was 80% and 
the pump rate was 10%. According to some references, the Mw of the polymer might play a 
role in the performance of a solid dispersion and better results can obtained with a lower Mw. 
However, at a higher ratio of PVP, the solubilization process may be neutralized by the 
diffusion process by increasing the viscosity of the solution around the particle. For these 
reasons, by the preparation of the spray-dried products were prepared in mass ratios of 1:5 
and 1:10 with PVP C-15 (SPD C-15) – because of its low Mw – and were dissolved in 30% 
ethanol. 
All of the products were stored under normal conditions at room temperature (22 oC). 
 
4.2. Physicochemical characterization of the products 
 
The OCA Contact Angle System (Dataphysics OCA 20, Dataphysics Inc., GmbH, 
Germany) was used for studies of the wettability of NIF and its products applying the circle 
fitting method.The powders were compressed under a pressure of 1 ton by a Specac hydraulic 
press (Specac Inc., USA). 
The partition coefficients (Kp ) of the samples were determined, which is defined as a 
ratio of drug concentration in the oil phase (usually represented by n-octanol) divided by the 
drug concentration in the aqueous phase measured at equilibrium under specified temperature 
in vitro in an oil/water two layer system. 
Saturation concentrations of solid dispersion systems were determined at 25 °C. NIF and 
its products were added to distilled water during continuous stirring until the excess drug 
appeared in suspended form. After filtration, the saturated solution was diluted and the drug 
concentration was determined spectrophotometrically. 
Particle size and distribution of solid dispersions were measured by LEICA Image 
Processing and Analysis System (LEICA Q500MC, LEICA Cambridge Ltd., England). 
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4.3. In vitro investigations 
 
Dissolution profiles were investigated by USP dissolution apparatus (USP rotating-basket 
dissolution apparatus, type DT; in simulated gastric medium (SGM) (pH = 1.1 ± 0.1; 94.00 g 
of 1 M HCl, 0.35 g of NaCl, 0.50 g of glycine to 1000 ml with distilled water), and simulated 
intestinal medium (SIM) (pH= 7.0 ± 0.1; 14.4 g of Na2HPO4·2H2O, 7.1 g of KH2PO4 to 1000 
ml with distilled water) with modified paddle method and their UV spectra were recorded by 
Unicam UV2/VIS spectrometer, Unicam Ltd., England. 
The following mathematical models were used to evaulate the results of the dissolution: 
Zero-order model, First-order model, Higuchi model, RRSBW model, Langenbucher, 
Modified Langenbucher and (Bt)a model. 
In vitro diffusion studies were performed from 100.0 mL of SGM or SIM to simulated 
plasma (SPL) (pH = 7.5 ± 0.1; 20.5 g of Na2HPO4·2H2O and 2.8 g of KH2PO4 to 1000 ml 
with distilled water) by Stricker's Sartorius apparatus (Sartorius-Membranfilter GmbH, 
Germany) where the artificial membrane was made of cellulose acetate (Schleicher & Schuell 
ME 29, Dassel, Germany: pore size 3 µm, diffusion surface 40 cm2). The diffusion rate 
constant, Kd was determined. 
 
4.4. Structural evaulation 
 
Microscopic observations of morphological features and their changes during heating 
were carried out with a LEICA Thermomicroscope (LEICA MZ 6, Germany). 
In DSC measurements applying Mettler Toledo DSC 821e thermal analysis system with 
STARe thermal analysis program V6.0 (Mettler Inc., Schwerzenbach, Switzerland) and argon 
was used as carrier gas, during the investigation. 
FT-IR spectra were measured on an AVATAR 330 FT-IR apparatus (Thermo Nicolet, 
USA). 
The physical state of the NIF in the different samples was evaulated by X-ray powder 
diffraction (XRPD). Diffraction patterns were obtained on a Philips PW 1710 diffractometer.  
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5. RESULTS AND DISCUSSION 
 
5.1. Investigation of cyclodextrin binary and ternary complexes 
 
The contact wetting angles of NIF, HP-β-CD, PVP K-90 and their products were 
determined in the 5th sec, because of the lowest SD (Table I). The contact angle of NIF was 
71.7 o, i.e. it is a very hydrophobic drug. 
 
Table I. Wetting angles of NIF and its products 
 [º]±SD [º]±SD [º]±SD [º]±SD [º]±SD [º]±SD 
NIF 71.3±3.2      
HP-β-CD 18.5±1.6      
PVP K-90 35.4±7.6 PM KP US PM+PVP KP+PVP 
2:1  30.4±4.5 40.9±0.6 42.3±4.6 30.7±0.7 42.3±6.7 
1:1  29.0±1.3 32.6±1.5 34.6±1.2 29.9±0.1 36.6±2.1 
1:2  24.8±2.2 25.2±2.3 27.0±2.0 28.7±1.3 30.0±2.0 
1:3  26.4±2.2 25.8±1.7 25.4±1.1 35.4±2.5 31.6±1.6 
 
The wetting angles of the investigated products in all cases lay between the values for CD 
and NIF. The investigation of the systems produced by the different preparation methods 
revealed that, with increasing HP-β-CD content, the contact wetting angles decreased (except 
for 1:3 PM+PVP and 1:3 KP+PVP). Usually the 1:2 and 1:3 ratios gave better results. To 
compare the results of wettability with n-octanol/water partition coefficient, in both study the 
1:2 PM+PVP and 1:3 ratios for all methods shown similar tendency. 
NIF has a high partition coefficient (1810.80), reflecting its poor water solubility and high 
affinity for n-octanol; its concentration in water at 22 oC is 26.75 µg/ml, while that in n-
octanol is 48439.07 µg/ml. The n-octanol/water partition coefficients revealed that the water 
solubility increase was generally better for the ternary than for the binary systems. The best 
partition coefficient results were 25.51 for 1:3 US; 5.94 for 1:2 PM+PVP and 9.13 for 1:3 
KP+PVP. The concentration of NIF in water could be increased even 15-fold (from 26.75 
µg/ml to 422.03 µg/ml). 
NIF has an acidic character, and its dissolution was therefore better in SIM (14.33 mg/100 
mL at 120 min) than in SGM (9.92 mg/100 mL at 120 min). In SGM, the dissolution 
increased in proportion to the CD content in all of the KPs, where the 1:3 KP gave the best 
dissolution result; the solubility increase was 4.4-fold as compared with the pure drug. Similar 
phenomena were observed for KPs+PVP. Elevation of the HP-β-CD ratio exerted a slight 
influence in increasing the dissolution of PMs, USs and PMs+PVP in SGM. In these cases, 
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the dissolution was prolonged, the quantity of NIF dissolved increasing only gradually. In 
SGM, extensive dissolution did not occur and the dissolutions of the different products were 
nearly the same as compared with NIF. In SIM the saturation concentration was attained in 
10−15 min. The maximum solubility increase (7-fold) was observed for the 1:1, 1:2 and 1:3 
ternary KPs, while a 3-fold increase was found for the 1:1 PM+PVP. The kinetic parameters 
show very well that the dissolution was dependent on the preparation methods because in 
some cases the kneading method and the use of PVP led to significantly higher dissolution 
rates as compared with NIF, especially in SIM. 
NIF has a 2.36 (10-3) cm/min as of Kd value compared with the Kd values of the samples, 
which were improved. With increase of the diffused drug concentration, the Kd values rose. 
The KPs+PVP showed the lowest Kd, 0.98, and for the USs a 2–3-fold rise was observed. For 
the binary products (PMs and KPs), on decrease of the amount of CD, Kd increased. 
The DSC curve indicates that the melting point of NIF is at 203.81 oC. To investigate the 
thermal properties of the systems, partial complexation is presumable in the cases of binary 
samples [the melting point decreased with increase of the CD concentration (190–180 oC)] 
and amorphisation or total complexation was detected for ternary systems (NIF melting was 
not observed in the DSC curves of the PMs+PVP) - Fig. 2. 
 
 
 
 
Fig. 2. DSC curves of PMs+PVP 
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5.2. Studies of solid dispersion systems 
 
About 50 % of the particles of the SPs and SPDs had a particle size between 10–20 µm. 
Reduction of the length and width of the particles was significant for the 1:2, 1:4 SPs and 1:5 
SPD (from ~ 46 µm to ~ 14 µm). According to the length's and width's reduction, the values 
of area and perimeter decreased significantly. This can result in an enhanced dissolution rate 
due to increases both in the surface area and solubilization. 
The investigation of the saturation concentration presented that the concentration of NIF 
in water could be increased even 15-fold (from 26.75 µg/ml to 413.33 µg/ml). The water 
solubility of NIF in the PMs was improved 2–3-fold and that of the SPs 4–8-fold. The results 
were outstanding in the case of the SPDs, where an 11–15-fold solubility increase was 
observed. The wetting angles of the investigated products were in all cases decreased. The 
investigation of the systems produced by physical mixing revealed that, with increasing PVP 
content, the contact wetting angles decreased: the 1:6 products were wetted 2–3 times better 
than NIF itself. The solvent and spray-drying methods gave the best results, except for the 1:1 
SP (7.5o) and 1:5 SPD (26.3o). 
A maximum solubility increase of 3.5-fold was observed for the SPs, and of 8-fold for the 
SPDs in SGM. NIF alone yielded the slowest initial dissolution rate (Fig. 3). 
 
Fig. 3. Dissolution of NIF and different types of solid dispersions in SGM 
 
All of the methods resulted in fast dissolution in SIM (Fig. 4). The saturation concentration 
was reached in 5−15 min. All of the solid dispersions resulted 100 % drug release in SIM 
while for the 1:4 and 1:6 PMs with PVP K-25 resulted 86 % drug release (for this reason, K-
25 was chosen at the beginning to prepare the SPs). 
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Fig. 4. Dissoultion curves of different types of solid dispersions in SIM 
 
To monitor the dissolution rate of PMs in SIM, in all cases were lower, than the pure drug, 
except for the 1:4 and 1:6 PM K-25, where 15 and 21-fold. Dissolution rates for solid 
dispersions were significantly greater than those for PMs and NIF. In SGM 2.3−5.26-fold 
improvement were marked and in SIM 26−51-fold. PVP may also have an enhancing effect 
on the wettability and dispersibility of the drug in the dissolution media. 
For all the products except the SPs, the diffusion was more advantageous than that of NIF 
into SGM. The diffusions of the products were also avaluable in the case of SGM. 
 
 
Fig. 5. Diffusion curves of NIF and SPs in SGM 
 
As regards the PMs containing PVP, the diffusion from the 1:4 compositions exhibited a 2-
fold increase after150 min. A 4.5-fold diffusion increase was measured for the SPs (Fig. 5) 
and a 2-fold improvement for the SPDs. The last part of the diffusion plots had a saturated 
character, as a consequence of the increased amount of diffused drug. 
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The DSC curves did not reveal a melting peak for NIF in any of the solid dispersions. This 
may be due to the interaction between NIF and PVP in these systems. In contrast with the 
XRPD patterns of the PMs K-25 (without any amorphous character of NIF), the melting point 
of the drug was not observed. This indicated a NIF:PVP solid-state interaction induced by 
heating. The different thermomicroscopic investigations indicated that, for the PMs K-25, 
NIF was dissolved in the melted PVP. Changes in the PMs K-25 during heating were detected 
by HSM. The photographs in Fig. 6 demonstrate the morphology of PM K-25 in 1:1 ratio 
from the beginning of heating up to 160 oC. With increase of temperature, the PVP began to 
melt, and above 130 oC its melting was complete. It may be seen that the NIF particles were 
dispersed in the melt and subsequently dissolved with rising temperature. During heating, the 
drug particle size was steadily reduced, showing its dissolution in the PVP melt. The NIF was 
completely dissolved in the melt of PVP at close to 160 oC, a temperature about 50 oC lower 
than the melting point of the pure drug. This finding can explain the absence of any sign of 
melting in the DSC thermograms of the PMs K-25. 
 
 
Fig. 6. HSM photographs of PM K-25 1:1 
 
The solvent evaporation method resulted essential changes in the molecular state of NIF by 
FT-IR. Two strong bands disappeared from the original spectra at 1615 and 1428 cm-1 a new 
one developed at 1683 cm-1. Fast evaporation of the solvent and the formation of an 
amorphous, highly dispersed, solid phase prevents the transfer of the proton, which resulted a 
higher energy state, higher equilibrium concentration and higher solubility. 
The XRPD peaks of NIF in the PMs K-25 were similar to those for the pure drug, 
indicating that the crystallinity of NIF was not changed in these products. However, the 
crystalline structures of NIF in all the solid dispersions were different from that of the pure 
drug, as revealed by the differences in their XRPD patterns. These patterns were similar to 
those for the PVPs. The absence of diffraction peaks indicated the presence of NIF in 
amorphous form (Fig. 7). 
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Fig. 7. XRPD patterns of NIF, PVP K-25, PM K-25 1:6 and SP K-25 1:6 
 
6. SUMMARY 
 
In consequence of the poor water-solubility of the pharmaceutical ingredient, NIF, my aim 
was to increase its solubility and dissolution rate by applying several methods. This work 
involved a preformulation study to introduce the technological possibilities of a generic 
formulation. 
The research work can be summarized as follows: 
 
1) The solubility-increasing effects of the available CD derivatives were determined 
under uniform conditions. It was found, that the solubility of NIF was always 
increased by the CDs, and especially for NIF with HP-β-CD to 2.5-fold. 
2) Different preparative mole ratios (2:1, 1:1, 1:2 and 1:3) and three methods (PMs-
physical mixtures, KPs-kneaded products and USs-ultrasonicated products) were 
applied to form complexes, and 15 m/m% PVP K-90 was used to prepare ternary 
systems (PMs+PVP and KPs+PVP) to improve the efficacy of complexation. 
3) To observe the good effect of a water-soluble polymer, PVP, on the complexation, 
solid dispersions were prepared in various mass ratios (1:1, 1:2, 1:4, 1:5, 1:6 and 
1:10), using different types of PVP and applying three methods (PMs, SPs-solvented 
products and SPDs-spray-dried products). 
4) The wettability study indicated that the products had a hydrophilic character as 
compared with NIF. Significantly lower wetting angles were measured for all samples, 
the decrease ranging from 71º to 26º. There was a parallel result for the wettability 
relative to the saturation concentration in water. A significant difference was observed 
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for the SPDs, where the concentration was 413 µg/ml compared with the pure NIF (26 
µg/ml). 
5) A concerns the morphology of the solid dispersions, determined via particle size 
analysis, the average lenght of the crystalline drug was changed during the solvent 
evaporation method, the size decreasing from 45 µm to 13 µm. These products have 
small particles, which is important in the formulation of solid dosage forms. 
6) 38 different samples were examined as regards their dissolution with the rotating 
basket tester in SGM and SIM. The dissolution was better in SIM for all samples, 
except the binary kneaded products. The same dissolution phenomena were observed 
for the KPs, KPs+PVP, SPs and SPDs in SGM, where a 4-fold solubility increase was 
detected. In SIM, depending the preparation methods, 3.5 (KPs), 7.5 (KPs+PVP) and 
14 (SPs and SPDs)-fold increases were demonstrated. 
7) The intensity of the dissolution depended on the preparation method. The PMs and the 
USs always displayed prolonged dissolution profiles. The addition of PVP and the use 
of an organic solvent, such as ethanol, methanol or acetone containing amorphous 
material led to rapid dissolution. It was also typical that the saturation concentration 
was reached in 5–10 min for solid dispersions, while the samples containing CDs 
needed 15–20 min to reach the same state. The dissolution rate increase was 1.5–2.5-
fold for binary and ternary systems with CD, and 5–51-fold for the solid dispersions. 
8) According to the BCS, NIF has good permeability and very bad solubility, which is 
reflected by the n-octanol distribution, which showed the high n-octanol solubility and 
low water solubility of NIF. The products resulted in a 2–4-fold better diffusion as 
compared with the original NIF in SGM. NIF had a Kd value of 2.36 10
-3 cm min-1, 
while the Kd values for the samples were improved. The SD and SPD with a mass ratio 
of 1:1 displayed the highest Kd values. 
9) The DSC curves demonstrated crystalline NIF for samples containing CD. When PVP 
was used, the melting point of the drug was not detected. During heating, the drug 
particle size was steadily reduced, showing its dissolution in the PVP melt. The NIF 
was completely dissolved in the melt of PVP at close to 157 oC, a temperature about 
50 oC lower than the melting point of the pure drug. This finding can explain the 
absence of any sign of melting in the DSC thermograms of the PMs K-25. 
10) The structural characterization, like the FT-IR spectra, did not show new bonds in the 
case of samples with CDs. Thus, no inclusion complexation was presumable. 
However, for the solid dispersion systems, where two strong bands disappeared from 
the original spectra, at 1615 and 1428 cm-1, a new one developed at 1683 cm-1. 
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11) The crystalline structures of NIF in all the solid dispersions were different from that of 
the pure drug, as revealed by the differences in their XRPD patterns. These patterns 
were similar to those for the PVPs. The absence of diffraction peaks indicated the 
presence of NIF in amorphous form. This is a higher energy state for the solid phase, 
resulting in a higher equilibrium concentration and a higher solubility. 
 
 
Fig. 8. Summarized technological protocol of the Thesis 
 
To summarize the results, the goal of this study that the solid dispersion systems are 
more favourable than using CD to improve the solubility and dissolution rate of nifluminic 
acid. Using CD, I suggest the ultrasonicated binary and the kneaded ternary 1:3 products to 
prepare semisolid dosage forms. In these cases the permeability and wettability properties of 
the drug are very useful. Spray-drying, like the solvent evaporation method using 30 v/v% of 
ethanol, resulted in rapid drug release, it is suitable for solid dosage form formulation. After 
this substantial preformulation study, further biopharmaceutical investigations should be 
performed, like gastric toxicity, blood level concentration and oedema inhibiting effect of the 
products. Fig. 8 present the steps of the technological protocol in the case of nifluminic acid. 
These methods may help by the generic formulation of other poorly water-soluble 
pharmacons, so the applied drug quantity and the unwanted side-effects can therefore be 
decreased. 
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